Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 1.00 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.74 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.74 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.74 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.74 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.74 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.74 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.74 |
| ▸ | ENTPD2 | Q9Y5L3 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514575 | 1.00 | P2RX3 (1.00) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL6514561 | 1.00 | P2RX3 (1.00) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL8861601 | 0.92 | P2RX3 (0.84) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL3318315 | 0.88 | P2RX3 (0.78) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL375601 | 0.85 | P2RY1 (1.00) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL375602 | 0.85 | P2RY1 (1.00) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL10120953 | 0.85 | P2RY1 (1.00) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL29381860 | 0.85 | P2RY1 (1.00) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL8861621 | 0.84 | P2RX3 (0.73) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL8861627 | 0.84 | P2RX3 (0.73) | P2RX3P2RY12P2RY1P2RY11ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255273-A1 | AUTOMATED CANINE LINE-UP FOR DETECTION DOG RESEARCH | TEXAS TECH UNIVERSITY SYSTEM | 2025-08-14 | — | — | US | disclosed |
| US-20250215329-A1 | METHOD AND SYSTEM FOR TREATING POLYMER WASTE COMPRISING HETEROATOMIC POLYMERS | POINTBREAK AS (NO) | 2025-07-03 | — | — | US | disclosed |
| US-12251861-B2 | Barriers for plastic preforms and containers and preforms and containers made therewith | PLASTIPAK BELGIUM BVBA (BE) | 2025-03-18 | — | — | US | disclosed |
| WO-2025051753-A1 | BLOWN FILM, METHOD OF PRODUCING IT, AND ARTICLES COMPRISING IT | PERSTORP AB (SE) | 2025-03-13 | — | — | WO | disclosed |
| US-20250064933-A1 | CHIMERIC ANTIGEN RECEPTORS COMPRISING A PDZ BINDING MOTIF | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4427907-A2 | BARRIERS FOR PLASTIC PREFORMS AND CONTAINERS, AND PREFORMS AND CONTAINERS MADE THEREWITH | Plastipak Belgium BVBA (BE) | 2024-09-11 | — | — | EP | disclosed |
| EP-3927516-B1 | BARRIERS FOR INJECTION MOLDED PLASTIC PREFORMS OR CONTAINERS AND INJECTION MOLDED PLASTIC PREFORMS OR CONTAINERS MADE THEREWITH | PLASTIPAK BELGIUM BVBA (BE) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024077230-A2 | AUTOMATED CANINE LINE-UP FOR DETECTION DOG RESEARCH | TEXAS TECH UNIVERSITY SYSTEM (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-3733171-B1 | COMPOSITIONS COMPRISING HMB AND ATP AS WELL AS THEIR USE | METABOLIC TECH LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4238559-A1 | COMBINATIONS OF ACETAMINOPHEN AND N-ACETYL CYSTEINE FOR THE TREATMENT OF PAIN AND FEVER | Centre Hospitalier Universitaire de Caen Normandie (FR) | 2023-09-06 | — | — | EP | disclosed |
| CN-116600660-A | Compositions and methods of use of beta-hydroxy-beta-methylbutyric acid (HMB) to improve muscle mass, strength, and muscle function without exercise | 代谢科技有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116535855-A | High heat-resistant transparent soluble polyimide film and preparation method and application thereof | 福州大学 | 2023-08-04 | — | — | CN | disclosed |
| CN-110741242-B | Ratio fluorescence imaging method | 艾维拉斯生物科学公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116199946-A | Ultra-high hardness rubber composite material with shape memory function and preparation method and application thereof | 北京化工大学 | 2023-06-02 | — | — | CN | disclosed |
| US-20230149426-A1 | Nutritional Intervention for Improving Muscular Function and Strength | METABOLIC TECH LLC (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4167761-A1 | COMPOSITIONS AND METHODS OF USE OF ?ETA-HYDROXY-?ETA-METHYLBUTYRATE (HMB) FOR IMPROVING MUSCLE MASS, STRENGTH AND MUSCULAR FUNCTION WITHOUT EXERCISE | Metabolic Technologies, LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11547713-B2 | Nutritional intervention for improving muscular function and strength | Metabolic Technologies, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-20220161470-A1 | BARRIERS FOR PLASTIC PREFORMS AND CONTAINERS AND PREFORMS AND CONTAINERS MADE THEREWITH | PLASTIPAK BELGIUM BVBA (BE) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | CCR5, ZC3HAV1L, CCRL2 | P2RX3 576/4885P2RY12 698/4885P2RY1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.